Glycopeptide susceptibility profiles of Staphylococcus haemolyticus bloodstream isolates.

F Biavasco, C Vignaroli, R Lazzarini, P E Varaldo
Author Information
  1. F Biavasco: Institute of Microbiology, University of Ancona, 60131 Ancona, Italy. f.biavasco@popcsi.unian.it

Abstract

Twelve clinical strains of Staphylococcus haemolyticus (eight methicillin resistant and three methicillin susceptible), isolated from blood cultures between 1982 and 1997, were investigated for teicoplanin and vancomycin susceptibility profiles. On the basis of conventional MIC tests and breakpoints, four isolates were susceptible (MICs, 1 to 8 microgram/ml) and eight were resistant (MICs, 32 to 64 microgram/ml) to teicoplanin while all were susceptible to vancomycin (MICs, 1 to 2 microgram/ml). All four strains for which the conventional teicoplanin MICs were within the range of susceptibility expressed heterogeneous resistance to teicoplanin and homogeneous vancomycin susceptibility. Of the eight strains for which the conventional teicoplanin MICs were within the range of resistance, six expressed heterogeneous and two expressed homogeneous teicoplanin resistance while seven showed heterogeneous vancomycin resistance profiles (with subpopulations growing on 8 microgram of the drug per ml at frequencies of >/=10(-6) for six strains and 10(-7) for one) and one demonstrated homogeneous vancomycin susceptibility. Of six bloodstream isolates of other staphylococcal species (S. aureus, S. epidermidis, and S. simulans), for all of which the conventional teicoplanin MICs were >/=4 microgram/ml and the vancomycin MICs were

References

  1. Clin Infect Dis. 1999 Oct;29(4):760-7 [PMID: 10589883]
  2. Clin Infect Dis. 1999 Oct;29(4):768-70 [PMID: 10589884]
  3. J Clin Microbiol. 2000 Feb;38(2):866-9 [PMID: 10655401]
  4. Eur J Clin Microbiol Infect Dis. 2000 Jun;19(6):403-17 [PMID: 10947214]
  5. N Engl J Med. 1987 Sep 17;317(12):766-8 [PMID: 3627189]
  6. J Antimicrob Chemother. 1988 Sep;22(3):321-4 [PMID: 2972670]
  7. Antimicrob Agents Chemother. 1989 Apr;33(4):460-6 [PMID: 2729941]
  8. J Infect Dis. 1990 Jan;161(1):45-51 [PMID: 2295858]
  9. J Clin Microbiol. 1990 Sep;28(9):2064-8 [PMID: 2229388]
  10. Antimicrob Agents Chemother. 1991 Jan;35(1):124-9 [PMID: 2014967]
  11. J Antimicrob Chemother. 1991 Jan;27(1):71-9 [PMID: 1828799]
  12. Eur J Clin Microbiol Infect Dis. 1991 Dec;10(12):1007-12 [PMID: 1802693]
  13. J Antimicrob Chemother. 1992 Dec;30(6):753-68 [PMID: 1289350]
  14. J Med Microbiol. 1993 Sep;39(3):204-10 [PMID: 8366519]
  15. J Antimicrob Chemother. 1993 Aug;32(2):267-78 [PMID: 8226428]
  16. J Hosp Infect. 1995 Nov;31(3):195-203 [PMID: 8586788]
  17. J Bacteriol. 1996 Aug;178(15):4696-703 [PMID: 8755902]
  18. Microb Drug Resist. 1996 Summer;2(2):239-43 [PMID: 9158766]
  19. Clin Microbiol Rev. 1997 Oct;10(4):781-91 [PMID: 9336672]
  20. Lancet. 1997 Dec 6;350(9092):1670-3 [PMID: 9400512]
  21. Antimicrob Agents Chemother. 1998 Jan;42(1):100-7 [PMID: 9449268]
  22. Lancet. 1998 Mar 21;351(9106):880-1 [PMID: 9525371]
  23. Eur J Clin Microbiol Infect Dis. 1998 Mar;17(3):143-50 [PMID: 9665294]
  24. J Antimicrob Chemother. 1998 Nov;42(5):673-5 [PMID: 9848458]
  25. J Clin Microbiol. 1999 Jan;37(1):39-44 [PMID: 9854061]
  26. N Engl J Med. 1999 Feb 18;340(7):517-23 [PMID: 10021472]
  27. Antimicrob Agents Chemother. 1999 Jul;43(7):1747-53 [PMID: 10390234]
  28. Antimicrob Agents Chemother. 1999 Aug;43(8):1914-8 [PMID: 10428912]
  29. J Infect Dis. 1986 Aug;154(2):349-52 [PMID: 2941491]
  30. Lancet. 1986 Oct 25;2(8513):973 [PMID: 2877149]
  31. Lancet. 1987 Jan 3;1(8523):39 [PMID: 2879112]
  32. N Engl J Med. 1987 Apr 9;316(15):927-31 [PMID: 3821839]

MeSH Term

Anti-Bacterial Agents
Drug Resistance, Microbial
Humans
Microbial Sensitivity Tests
Staphylococcus
Teicoplanin
Vancomycin

Chemicals

Anti-Bacterial Agents
Teicoplanin
Vancomycin

Word Cloud

Created with Highcharts 10.0.0teicoplaninsusceptibilityvancomycinMICsheterogeneousprofilesconventionalmicrogram/mlstrainsisolatesresistancehomogeneousShaemolyticuseightthreesusceptible8expressedsixshowedoneStaphylococcusmethicillinresistantMICtestsfour1withinrangesubpopulationsgrowingmicrogramdrugpermlbloodstreamglycopeptidesTwelveclinicalisolatedbloodcultures19821997investigatedbasisbreakpoints32642twosevenfrequencies>/=10-610-7demonstratedstaphylococcalspeciesaureusepidermidissimulans>/=4noneexhibitedfoundstrainresultsstudyindicateresponsecommonfeaturesuggestdeterminedmaypredictiveoutcomeglycopeptidetherapyGlycopeptide

Similar Articles

Cited By